Академический Документы
Профессиональный Документы
Культура Документы
Corresponding author
Neil A. Hagen, MD analgesic ladder [1]. However, some cancer pain prob-
Tom Baker Cancer Centre, Alberta Cancer Board; Division of lems are predictably more difficult to manage. Specific
Palliative Medicine, University of Calgary, 1331 29th Street NW, pain syndromes or clinical scenarios that have been
Calgary, Alberta T2N 4N2, Canada. associated with a poorer prognosis include cancer-related
E-mail: neilha@cancerboard.ab.ca neuropathic pain, pelvic pain, pain in patients with delir-
Current Pain and Headache Reports 2008, 12:241248 ium, pain in patients with a history of substance abuse,
Current Medicine Group LLC ISSN 1531-3433
breakthrough pain, and several others [2]. Breakthrough
Copyright 2008 by Current Medicine Group LLC
cancer pain can have a good outcome but requires a sepa-
rate set of strategies from those usually used to assess and
manage chronic cancer pain.
Cancer pain is highly prevalent and often severe. Fortu-
nately, most cancer pain can be readily managed, with
up to 90% of patients responding well to standard inter-
ventions. However, breakthrough cancer painbrief
The Definition of Breakthrough Pain
Breakthrough pain was originally defi ned as a transi-
ares of severe pain superimposed on baseline painis
tory increase in pain to greater than moderate intensity
common, difcult to manage, and often negatively
(that is, to an intensity of severe or excruciating),
impacts patients quality of life. Breakthrough cancer
which occurs on a baseline pain of moderate intensity
pain is traditionally managed with oral, immediate-
or less (that is, no pain or pain of mild or moderate
release opioids. However, because of its sudden onset
intensity) [3]. Existing terminology characterizing the
and severity, oral opioids often fall short of providing
phenomenology of breakthrough pain reflects its several
adequate control. Research into novel approaches to
clinically important dimensions. Because wide variations
pain management has identied several innovative strat-
in reported prevalence rates of breakthrough pain are
egies for this difcult cancer pain problem. We describe
likely in part due to different meanings or understand-
current approaches to assess, dene, characterize, and
ings of the concept of breakthrough pain [4], there is a
treat breakthrough cancer pain, and summarize recent
need for widely accepted and validated pain terminology.
clinical research on novel agents, novel routes of drug
Vocabulary surrounding breakthrough pain has been
delivery, and other advances in its management.
a topic of considerable debate and was the subject of a
major consensus meeting of an expert working group
of the European Association for Palliative Care [4]. The
Introduction group recommended the use of a broader, simpler term
Cancer pain is highly prevalent. Depending on the clinical such as episodic or transient pain, as the English
circumstances, such as type of cancer, extent of disease, term breakthrough has no literal translation in many
and other important clinical variables, pain is present other languages. Although experts and clinicians in the
in 30% to 70% of patients early in their disease course field have grappled with standardized defi nitions of pain,
and becomes more prevalent and severe as the disease to date no such universal taxonomy is available; at present
advances. Fortunately, most cancer pain can be readily the term breakthrough pain remains widely used, and
managed by interventions available at local pharmacies, hence, the title of this article.
with up to 90% of patients responding well to simple One recent effort to characterize patients experi-
interventions such as the World Health Organizations ence of breakthrough pain involved the development of
242 Cancer Pain
a comprehensive clinical research tool [5]. Through an The Prevalence of Breakthrough Pain
iterative, organized discussion, several defi nitions for The demographics of cancer-related breakthrough pain
breakthrough painrelated terms were agreed to by inter- have been characterized in a range of clinical situations
national experts on the topic (Table 1) [5]. With time and a variety of patient populations. An early study of
and further input, these defi nitions will likely continue to hospitalized cancer pain patients found that about two
evolve; for now, they help to simplify the area. thirds of patients with otherwise well-controlled baseline
pain had episodes of breakthrough pain each day [3].
Other studies conducted in different countries and prac-
Types of Breakthrough Pain tice settings have described breakthrough pain prevalence
In general, breakthrough pain can be characterized as ranging from 40% to upwards of 80%, depending on the
incident pain, spontaneous pain, or end-of-dose pain setting [4]. Most patients with cancer of the pancreas will
[3,6]. Incident pain refers to physical activities such as have spontaneous flares of pain, although the mechanism
weight-bearing in a patient with bone metastases, or is not understood [7 ]; a recent report has highlighted the
dressing changes that can be predicted to worsen pain. high prevalence of spontaneous, unpredictable episodes of
Incident pain can include events that are volitional, such breakthrough pain in many kinds of cancer [8].
as pain with voluntary movement, or nonvolitional,
such as breakthrough pain caused by a bowel motion in
a patient with bulky pelvic cancer. End-of-dose failure Assessment of Breakthrough Pain
is another predictable kind of breakthrough pain that is The pain history should include key elements that char-
related to pharmacokinetic factors, in which the baseline acterize the salient clinical features of breakthrough pain
pain increases before the next scheduled dose of analgesic. (Fig. 1), in addition to standardly described approaches
The interval between the onset of end-of-dose failure and to the cancer pain history [6]. Clinicians have often
the next scheduled pain medication can give the clinician implemented routine use of several validated pain tools
an idea of the degree of baseline medication underdos- to complement the pain history, including one or more of
ing. Breakthrough pain can also occur without any clear the following: the Brief Pain Inventory, Neuropathic Pain
antecedent cause, for reasons that are difficult to fully Scale, Edmonton Symptom Assessment Scale, Edmonton
understand. An example of spontaneous breakthrough Classification Scale, Memorial Pain Assessment Card,
pain is a circadian flare of pain, with pain that predict- Memorial Pain Assessment Scale, McGill Pain Ques-
ably worsens in the afternoon or evening. tionnaire, visual analogue scales, numerical scales, and
Assessment and Management of Breakthrough Pain in Cancer Patients Hagen et al. 243
others. However, these tools have more limited use in the Management of Cancer-Related
assessment of breakthrough pain. At present, no widely Breakthrough Pain
used clinical tool is available to assess breakthrough As described earlier, breakthrough pain is commonly
pain. In an effort to improve and support research in quite sudden in onset. One study identified a median time
the area of breakthrough pain, we have developed the from onset to peak pain of only 3 minutes [3]. Further,
Alberta Breakthrough Pain Assessment Tool for research breakthrough pains are often brief in duration and have
purposes, which has undergone content and construct been described to have a median duration of about 30
validity testing and is now available for use [5]. Figure minutes [3,10]. Because of its sudden onset, severity,
1 depicts the key elements for assessment of the patient and brief duration, an analgesic ideal for breakthrough
with cancer-related breakthrough pain, which provided pain would have very rapid onset and brief duration of
the foundation for the development of the Alberta Break- analgesic effect. A widely cited approach to managing
through Pain Assessment Tool. cancer-related breakthrough pain is the use of oral imme-
Interference with function is one of the key ways that diate-release opioids. However, oral immediate-release
breakthrough cancer pain negatively impacts quality of morphine fi rst appears in the blood close to half an hour
life [8]. Patients may report good control of pain while at after it is ingested [11]. In fact, in a recent study evaluat-
rest, only to have severe pain with movement. The extent ing the analgesic effectiveness of several breakthrough
of pains interference with function has been captured in pain rescue medications among hospice patients taking
a variety of quality-of-life instruments such as the Brief oral preparations (including morphine, oxycodone, or
Pain Inventory and, from a pragmatic perspective, may be hydromorphone), the average time to meaningful pain
one of the most important dimensions of the overall pain relief was greater than 30 minutes, whereas the average
experience that patients can relate to clinicians. duration of breakthrough pain in these patients was only
The physical examination is an essential component 35 minutes [10]. There appears to be a critical mismatch
of the clinical assessment process to ensure a thor- between the early pharmacokinetics of oral immediate-
ough understanding of the cancer pain experience [6 ]. release opioids and the sudden onset and brief duration
Most authorities agree that the physical examination of breakthrough pain.
of the cancer pain patient includes a general physical Even more curious are the early pharmacodynamics
examination based on a systems approach; an oncologic of opioids in breakthrough pain (ie, the onset of analge-
examination to assess extent of disease; and a regional sic effect over time). Studies have identified an apparent
pain examination to identify pathology in the area of placebo phenomenon, whereby there is an onset of anal-
pain. Bedside provocative maneuvers have been shown to gesic effect of oral opioids or other agents much earlier
accurately reproduce cancer pain in most cases and can than could be accounted for by the anticipated increase
lead to a more accurate pain diagnosis [9]. This assess- in blood levels [12 ,13]. The phenomenon is of major
ment technique may be useful in characterizing pain and clinical effect within about 20 minutes after ingestion of
can guide selection of treatment options. However, bed- analgesics but has been described to occur as early as 10
side provocative maneuvers are not as able to reproduce minutes after administration. Although neither studied nor
certain specific pain syndromes: spontaneous, paroxys- named, it could be described as an anticipatory placebo
mal spells of pain, some kinds of neuropathic pain, and effect. Despite the presence of this earlier-than-expected
some clinical situations of steady headache. effect of immediate-release analgesics, cancer-related
244 Cancer Pain
breakthrough pain remains a difficult-to-manage pain opioid, representing 10% to 20% [14], 5% to 15% [15], or
syndrome, and more effective interventions with faster one sixth of the total daily dose of opioids [1]. However,
onset could potentially be of great benefit. recent research suggests that the effective dose of opioids
is only poorly related to the total daily dose of opioid. In
a large study of 188 cancer patients with breakthrough
Conventional and Emerging Treatments pain, the effective breakthrough opioid dose ranged from
for Breakthrough Pain 10% to 20% of the daily dose of opioid about one third of
Standard approaches to management of breakthrough the time; the dose was outside of that range in the remain-
pain include recommendations for immediate-release oral ing two thirds. The effective breakthrough opioid dose
Assessment and Management of Breakthrough Pain in Cancer Patients Hagen et al. 245
size was as small as 1% of the total daily dose of opioid four controlled trials of OTFC for cancer pain have been
and as much as 71% of the total daily dose of opioid. published (Table 2). Its onset of action is faster than oral
The authors concluded that breakthrough opioid dos- opioids. However, the agent is expensive. Subcutaneous
age should be titrated individually for each patient, and infusions have been widely used for breakthrough pain
with a titration strategy separate from that of the base- and may be preferred by patients over intravenous or
line cancer pain medication [16]. However, starting with intramuscular routes of drug administration [1]. Rectal
about 10% of daily opioid dose seems safe in most clinical suppositories of acetaminophen or immediate-release
circumstances and has been widely accepted [17 ]. opioids can be used when the oral route is not feasible [1].
Although oral immediate-release opioids are often Rarely, patients with gastrointestinal disease have self-
effective for breakthrough pain, a range of other routes, administered slow- and immediate-release opioids via the
drugs, and drug delivery systems have been evaluated vaginal route, with good effect. A small pharmacokinetic
partly to identify ways to achieve faster relief of pain. study described absorption of fentanyl administered in a
Studies have evaluated transdermal, intravenous, subcu- vaginal suppository [48].
taneous, sublingual, transbuccal, intranasal, and inhaled Although not the focus of this review, it is worth
routes of administration of analgesics for breakthrough noting that several of these emerging treatments for
pain. Table 2 highlights key publications selected from breakthrough pain have been evaluated in populations of
a large, emerging body of literature. The most exten- patients with nonmalignant pain syndromes. Transdermal
sively studied novel route for breakthrough medication is fentanyl has been used to treat pain from acute pancreati-
transbuccal (ie, cheek mucosal membrane), using the oral tis [49], and intranasal ketamine was effective in treating
transmucosal fentanyl citrate (OTFC) lozenge; to date, patients with chronic, nonmalignant pain [50]. Random-
246 Cancer Pain
ized controlled trials evaluating fentanyl buccal tablet A reasonable approach to manage cancer-related break-
effectiveness have reported decreases in breakthrough through pain is with the use of oral immediate-release
pain intensity within 10 minutes of administration among opioids, beginning with approximately 10% of the
patients with chronic low back pain [51] and chronic non- daily dose of opioid. The breakthrough pain medication
cancer neuropathic pain [52]. Similarly, OTFC has been should be titrated upward or downward according to
shown effective in treating chronic noncancer pain [53] effect. When pain is predictable, oral immediate-release
and migraine pain [54]. opioids should be taken well in advance (eg, 30 minutes
In order to identify interventions that are more rapid in or longer before the expected pain). For breakthrough
onset, investigators have considered not only the route of pains that are sudden in onset and severe, alternative
administration but also the speed and magnitude of anal- routes (eg, intranasal or sublingual) and medications
gesic effect once the drug has been ingested. Some agents (eg, fentanyl or sufentanil) should be considered. Con-
can be predicted to have more rapid onset of analgesic tinuity of care is the key to providing the best possible
effect than traditional opioids. For example, intravenous outcome, along with careful attention to the underlying
bolus morphine has an onset of analgesic effect of about 5 mechanisms of pain and effective treatment of the causes
minutes after administration, with a lag of the peak effect whenever possible.
beyond 20 minutes [55]. The peak effect occurs about 1
hour after injection of intramuscular morphine [56]. The
peak effect of oral morphine is close to 2 hours after inges- Disclosures
tion [56]. Intravenous bolus hydromorphone has a rapid No potential conflicts of interest relevant to this article were reported.
initial effect similar to that of intravenous morphine,
with a faster peak analgesic effect of between 10 and 20
minutes after injection [55]. References and Recommended Reading
The onset and peak of opioid analgesic effect is Papers of particular interest, published recently,
influenced by several well-defi ned factors; of these, lipid have been highlighted as:
solubility is one of the most important. Fat-soluble opi- Of importance
oids include fentanyl series agents (fentanyl, sufentanil, Of major importance
and alfentanil), methadone, and others. Oral methadone 1. Hanks G, Cherny NI, Fallon M: Opioid analgesic therapy.
in particular appears to have an onset of action within In Oxford Textbook of Palliative Medicine, edn 3. Edited
10 minutes [23], and published evidence suggests it may by Doyle D, Hanks G, Cherny N, Calman K. Oxford:
Oxford University Press; 2004:316 341.
have a faster onset of action than oral morphine in can-
2. Fainsinger RL, Nekolaichuk CL, Lawlor PG, et al.: A
cer patients [10]. With this in mind, in a preliminary multicenter study of the revised Edmonton Staging System
study of the early pharmacodynamics of sublingual for classifying cancer pain in advanced cancer patients.
methadone, a highly fat-soluble opioid, investigators J Pain Symptom Manage 2005, 29: 224237.
3. Portenoy RK, Hagen NA: Breakthrough pain: defi nition,
found evidence that it may have an analgesic effect as prevalence and characteristics. Pain 1990, 41: 273281.
short as 5 minutes after administration [35]. However, 4. Mercadante S, Radbruch L, Caraceni A, et al.: Episodic
further work with this approach is needed before wide- (breakthrough) pain: consensus conference of an expert
working group of the European Association for Palliative
spread use. Other studies involving sublingual sufentanil Care. Cancer 2002, 94:832 839.
and fentanyl [3638] also suggest a very rapid onset of 5. Hagen NA, Stiles C, Nekolaichuk C, et al.: The Alberta
these lipid-soluble opioids. Breakthrough Pain Assessment Tool for cancer patients:
A range of nonopioid analgesic medications have also a validation study using a Delphi process and patient
think-aloud interviews. J Pain Symptom Manage 2008,
been evaluated. Sublingual ketamine for breakthrough 35:136152.
pain was evaluated in three cancer patients receiving This report describes a new tool to characterize the experience of
spinal analgesics; effective pain control was achieved breakthrough pain. The tool can be downloaded at http://www.
cancerpainnet.ca/research_tools (follow the links to ABPAT, the
within 10 minutes for each of 12 breakthrough pain epi- Alberta Breakthrough Pain Assessment Tool).
sodes evaluated [39]. Inhaled nitrous oxide use by seven 6. Foley K: Acute and chronic cancer pain syndromes. In
patients with cancer-related incident pain resulted in a Oxford Textbook of Palliative Medicine. edn 3. Edited by
Doyle D, Hanks G, Cherny N, Calman K. Oxford: Oxford
nonsignificant reduction in pain change scores (baseline University Press; 2004:298 316.
to peak pain), compared with inhaled placebo gas in a 7. Saltzburg D, Foley KM: Management of pain in pancreatic
crossover design over 2 consecutive days [47 ]. cancer. Surg Clin North Am 1989, 69: 629 649.
8. Portenoy RK, Payne D, Jacobsen P: Breakthrough pain:
characteristics and impact in patients with cancer pain.
Pain 1999, 81:129134.
Conclusions 9. Hagen NA: Reproducing a cancer patients pain on physical
Breakthrough cancer pain is highly prevalent and nega- examination: bedside provocative maneuvers. J Pain Symptom
Manage 1999, 18:406 411.
tively impacts quality of life. A wide range of treatments 10. Zeppetella G: Opioids for cancer breakthrough pain: a pilot
are standardly available, and ongoing research holds the study reporting patient assessment of time to meaningful
promise for more effective agents over the coming years. pain relief. J Pain Symptom Manage 2008, 35:563567.
Assessment and Management of Breakthrough Pain in Cancer Patients Hagen et al. 247
11. Collins SL, Faura CC, Moore RA, McQuay HJ: Peak plasma 29. Mercadante S, Villari P, Ferrera P, et al.: Safety and effective-
concentrations after oral morphine: a systematic review. ness of intravenous morphine for episodic breakthrough
J Pain Symptom Manage 1998, 16:388 402. pain in patients receiving transdermal buprenorphine. J Pain
12. Portenoy RK, Payne R, Coluzzi P, et al.: Oral transmucosal Symptom Manage 2006, 32:175179.
fentanyl citrate (OTFC) for the treatment of breakthrough 30. Mercadante S, Villari P, Ferrera P, et al.: Transmucosal
pain in cancer patients: a controlled dose titration study. fentanyl vs intravenous morphine in doses proportional to
Pain 1999, 79:303 312. basal opioid regimen for episodic-breakthrough pain. Br J
13. Farrar JT, Cleary J, Rauck R, et al.: Oral transmucosal fen- Cancer 2007, 96:18281833.
tanyl citrate: randomized, double-blinded, placebo-controlled 31. Flogegard H, Ljungman G: Characteristics and adequacy of
trial for treatment of breakthrough pain in cancer patients. intravenous morphine infusions in children in a paediatric
J Natl Cancer Inst 1998, 90:611 616. oncology setting. Med Pediatr Oncol 2003, 40: 233238.
14. Benedetti C, Brock C, Cleeland C, et al.: NCCN Practice 32. Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI:
Guidelines for Cancer Pain. Oncology (Williston Park) Comparison of continuous subcutaneous and intravenous
2000, 14:135150. hydromorphone infusions for management of cancer pain.
15. Cherny NI, Portenoy RK: Cancer pain management. Current Lancet 1991, 337:465 468.
strategy. Cancer 1993, 72:33933415. 33. Miller MG, McCarthy N, OBoyle CA, Kearney M:
16. Hagen NA, Fisher K, Victorino C, Farrar JT: A titration Continuous subcutaneous infusion of morphine vs. hydro-
strategy is needed to manage breakthrough cancer pain morphone: a controlled trial. J Pain Symptom Manage
effectively: observations from data pooled from three clinical 1999, 18:916.
trials. J Palliat Med 2007, 10:4755. 34. Enting RH, Mucchiano C, Oldenmenger WH, et al.: The
17. Librach SL, Squires BP: The Pain Manual: Principles and pain pen for breakthrough cancer pain: a promising
Issues in Cancer Pain Management. Montreal: Pegasus treatment. J Pain Symptom Manage 2005, 29: 213217.
Healthcare International; 2001. 35. Hagen NA, Fisher K, Stiles C: Sublingual methadone for the
18. Finn JW, Walsh TD, MacDonald N, et al.: Placebo-blinded management of cancer-related breakthrough pain: a pilot
study of morphine sulfate sustained-release tablets and study. J Palliat Med 2007, 10:331 337.
immediate-release morphine sulfate solution in outpatients 36. Kunz KM, Theisen JA, Schroeder ME: Severe episodic pain:
with chronic pain due to advanced cancer. J Clin Oncol management with sublingual sufentanil. J Pain Symptom
1993, 11:967972. Manage 1993, 8:189190.
19. Deschamps M, Band PR, Hislop TG, et al.: The evaluation 37. Zeppetella G: Sublingual fentanyl citrate for cancer-related
of analgesic effects in cancer patients as exemplified by a breakthrough pain: a pilot study. Palliat Med 2001,
double-blind, crossover study of immediate-release versus 15:323 328.
controlled-release morphine. J Pain Symptom Manage 38. Lennernas B, Hedner T, Holmberg M, et al.: Pharma-
1992, 7:384 392. cokinetics and tolerability of different doses of fentanyl
20. Freye E, Levy JV, Braun D: Effervescent morphine results in following sublingual administration of a rapidly dissolving
faster relief of breakthrough pain in patients compared to tablet to cancer patients: a new approach to treatment of
immediate release morphine sulfate tablet. Pain Pract 2007, incident pain. Br J Clin Pharmacol 2005, 59: 249253.
7:324331. 39. Mercadante S, Arcuri E, Ferrera P, et al.: Alternative treat-
21. Citron ML, Kaplan R, Parris WC, et al.: Long-term admin- ments of breakthrough pain in patients receiving spinal
istration of controlled-release oxycodone tablets for the analgesics for cancer pain. J Pain Symptom Manage 2005,
treatment of cancer pain. Cancer Invest 1998, 16:562571. 30:485 491.
22. Palangio M, Northfelt DW, Portenoy RK, et al.: Dose conver- 40. Slatkin NE, Xie F, Messina J, Segal TJ: Fentanyl buccal
sion and titration with a novel, once-daily, OROS osmotic tablet for relief of breakthrough pain in opioid-tolerant
technology, extended-release hydromorphone formulation in patients with cancer-related chronic pain. J Support Oncol
the treatment of chronic malignant or nonmalignant pain. 2007, 5:327334.
J Pain Symptom Manage 2002, 23:355368. 41. Portenoy RK, Taylor D, Messina J, Tremmel L: A random-
23. Fisher K, Stiles C, Hagen NA: Characterization of the early ized, placebo-controlled study of fentanyl buccal tablet for
pharmacodynamic profi le of oral methadone for cancer- breakthrough pain in opioid-treated patients with cancer.
related breakthrough pain: a pilot study. J Pain Symptom Clin J Pain 2006, 22:805 811.
Manage 2004, 28: 619 625. This trial, with its state-of-the-art design, is a strong example of an
24. Sloan PA, Moulin DE, Hays H: A clinical evaluation of innovative approach to managing breakthrough cancer pain.
transdermal therapeutic system fentanyl for the treatment 42. Christie JM, Simmonds M, Patt R, et al.: Dose-titration,
of cancer pain. J Pain Symptom Manage 1998, 16:102111. multicenter study of oral transmucosal fentanyl citrate for
25. Menten J, Desmedt M, Lossignol D, Mullie A: Longitudinal the treatment of breakthrough pain in cancer patients using
follow-up of TTS-fentanyl use in patients with cancer- transdermal fentanyl for persistent pain. J Clin Oncol 1998,
related pain: results of a compassionate-use study with 16:3238 3245.
special focus on elderly patients. Curr Med Res Opin 2002, 43. Coluzzi PH, Schwartzberg L, Conroy JD, et al.: Breakthrough
18:488 498. cancer pain: a randomized trial comparing oral transmucosal
26. Sittl R, Griessinger N, Likar R: Analgesic effi cacy and fentanyl citrate (OTFC) and morphine sulfate immediate
tolerability of transdermal buprenorphine in patients release (MSIR). Pain 2001, 91:123130.
with inadequately controlled chronic pain related to 44. Pavis H, Wilcock A, Edgecombe J, et al.: Pilot study of
cancer and other disorders: a multicenter, randomized, nasal morphine-chitosan for the relief of breakthrough pain
double-blind, placebo-controlled trial. Clin Ther 2003, in patients with cancer. J Pain Symptom Manage 2002,
25:150 168. 24:598 602.
27. Likar R, Kayser H, Sittl R: Long-term management of 45. Fitzgibbon D, Morgan D, Dockter D, et al.: Initial pharma-
chronic pain with transdermal buprenorphine: a multi- cokinetic, safety and efficacy evaluation of nasal morphine
center, open-label, follow-up study in patients from three gluconate for breakthrough pain in cancer patients. Pain
short-term clinical trials. Clin Ther 2006, 28:943952. 2003, 106:309 315.
28. Mercadante S, Villari P, Ferrera P, et al.: Safety and effective- 46. Zeppetella G: An assessment of the safety, efficacy, and
ness of intravenous morphine for episodic (breakthrough) acceptability of intranasal fentanyl citrate in the manage-
pain using a fi xed ratio with the oral daily morphine dose. ment of cancer-related breakthrough pain: a pilot study.
J Pain Symptom Manage 2004, 27:352359. J Pain Symptom Manage 2000, 20: 253258.
248 Cancer Pain
47. Parlow JL, Milne B, Tod DA, et al.: Self-administered 52. Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal
nitrous oxide for the management of incident pain in tablet for the relief of breakthrough pain in opioid-tolerant
terminally ill patients: a blinded case series. Palliat Med adult patients with chronic neuropathic pain: a multicenter,
2005, 19:3 8. randomized, double-blind, placebo-controlled study. Clin
48. Fisher K, Stiles C, Heim B, Hagen NA: Can fentanyl be sys- Ther 2007, 29:588 601.
temically absorbed when administered vaginally? A feasibility 53. Taylor DR, Webster LR, Chun SY, et al.: Impact of break-
study. J Palliat Care 2006, 22:5456. through pain on quality of life in patients with chronic,
49. Stevens M, Esler R, Asher G: Transdermal fentanyl for the noncancer pain: patient perceptions and effect of treatment
management of acute pancreatitis pain. Appl Nurs Res with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
2002, 15:102110. Pain Med 2007, 8: 281288.
50. Carr DB, Goudas LC, Denman WT, et al.: Safety and 54. Landy SH: Oral transmucosal fentanyl citrate for the treat-
efficacy of intranasal ketamine for the treatment of break- ment of migraine headache pain in outpatients: a case series.
through pain in patients with chronic pain: a randomized, Headache 2004, 44:762766.
double-blind, placebo-controlled, crossover study. Pain 55. Coda B, Tanaka A, Jacobson RC, et al.: Hydromorphone
2004, 108:1727. analgesia after intravenous bolus administration. Pain
51. Portenoy RK, Messina J, Xie F, Peppin J: Fentanyl buccal 1997, 71:41 48.
tablet (FBT) for relief of breakthrough pain in opioid- 56. Jaffe JH, Martin WR: Opioid analgesics and antagonists.
treated patients with chronic low back pain: a randomized, In The Pharmacological Basis of Therapeutics. Edited
placebo-controlled study. Curr Med Res Opin 2007, by Gillman AG, Goodman LS, Gilman A. New York:
23: 223233. Macmillan Co.; 1980: 494534.